Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H5HZ
|
|||
| Former ID |
DIB007148
|
|||
| Drug Name |
Etamicastat
|
|||
| Synonyms |
BIA-5453; Dopamine beta hydroxylase inhibitors (cardiovascular diseases), BIAL; Dopamine beta hydroxylase inhibitors (cardiovascular diseases), Portela
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Heart failure [ICD-11: BD10-BD13; ICD-10: I50, I50.9; ICD-9: 428] | Phase 2 | [1] | |
| Company |
Portela & Ca SA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H15F2N3OS
|
|||
| Canonical SMILES |
C1C(COC2=C1C=C(C=C2F)F)N3C(=CNC3=S)CCN
|
|||
| InChI |
1S/C14H15F2N3OS/c15-9-3-8-4-11(7-20-13(8)12(16)5-9)19-10(1-2-17)6-18-14(19)21/h3,5-6,11H,1-2,4,7,17H2,(H,18,21)/t11-/m1/s1
|
|||
| InChIKey |
CWWWTTYMUOYSQA-LLVKDONJSA-N
|
|||
| CAS Number |
CAS 760173-05-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine beta hydroxylase (DBH) | Target Info | Inhibitor | [2] |
| BioCyc | Catecholamine biosynthesis | |||
| KEGG Pathway | Tyrosine metabolism | |||
| Metabolic pathways | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Dopamine receptor mediated signaling pathway | ||||
| Pathwhiz Pathway | Catecholamine Biosynthesis | |||
| Tyrosine Metabolism | ||||
| WikiPathways | Monoamine Transport | |||
| Biogenic Amine Synthesis | ||||
| Metabolism of amino acids and derivatives | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034724) | |||
| REF 2 | Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-beta-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D. 2010;10(4):225-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.